Trial Profile
A clinical study of IBIO-200 for COVID-19 infection
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 03 Apr 2020
At a glance
- Drugs IBIO 200 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 03 Apr 2020 New trial record
Most Recent Events
Trial Overview
Purpose
This trial will evaluate IBIO-200 for the treatment of COVID-19 infection.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Affiliations iBio Inc
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase I
- Location Unknown
- Focus Adverse reactions
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| IBIO 200Primary Drug |
-
|
-
|
IBIO-200
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 03 Apr 2020 | New trial record | New trial record Updated 03 Apr 2020 |
References
-
iBio Inc. iBio Announces Advancement of COVID-19 Vaccine Program. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG